Prime Medicine, Inc.
PRME
$3.27
-$0.03-0.91%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.03M | 4.63M | 5.98M | 4.96M | 3.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.03M | 4.63M | 5.98M | 4.96M | 3.85M |
| Cost of Revenue | 116.02M | 122.48M | 121.87M | 118.22M | 119.23M |
| Gross Profit | -111.99M | -117.85M | -115.90M | -113.26M | -115.38M |
| SG&A Expenses | 56.47M | 52.35M | 49.91M | 52.80M | 52.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 210.65M | 212.98M | 209.94M | 209.18M | 210.36M |
| Operating Income | -206.61M | -208.35M | -203.96M | -204.22M | -206.52M |
| Income Before Tax | -198.37M | -201.14M | -197.34M | -199.28M | -202.15M |
| Income Tax Expenses | -- | -- | -- | -- | -134.00K |
| Earnings from Continuing Operations | -198.37 | -201.14 | -197.34 | -199.28 | -202.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -198.37M | -201.14M | -197.34M | -199.28M | -202.01M |
| EBIT | -206.61M | -208.35M | -203.96M | -204.22M | -206.52M |
| EBITDA | -199.14M | -201.03M | -196.80M | -197.38M | -200.01M |
| EPS Basic | -1.26 | -1.38 | -1.44 | -1.57 | -1.62 |
| Normalized Basic EPS | -0.80 | -0.87 | -0.91 | -0.98 | -1.02 |
| EPS Diluted | -1.26 | -1.38 | -1.44 | -1.57 | -1.62 |
| Normalized Diluted EPS | -0.80 | -0.87 | -0.91 | -0.98 | -1.02 |
| Average Basic Shares Outstanding | 644.09M | 597.87M | 551.50M | 510.76M | 500.76M |
| Average Diluted Shares Outstanding | 644.09M | 597.87M | 551.50M | 510.76M | 500.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |